GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL股票上漲，因公司提供了PATHFINDER 2和NHS-Galleri註冊臨床試驗的最新情況，評估Galleri多癌症早期檢測測試。
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL股票上漲，因公司提供了PATHFINDER 2和NHS-Galleri註冊臨床試驗的最新情況，評估Galleri多癌症早期檢測測試。